<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524561</url>
  </required_header>
  <id_info>
    <org_study_id>2009P002326</org_study_id>
    <secondary_id>R01CA136918</secondary_id>
    <nct_id>NCT02524561</nct_id>
  </id_info>
  <brief_title>KEEPS Mammographic Density And Breast Health Ancillary Study</brief_title>
  <acronym>KEEPS MDBHAS</acronym>
  <official_title>KEEPS Mammographic Density And Breast Health Ancillary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kronos Longevity Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined estrogen and progestin therapy has been shown to increase mammographic density and
      incidence of breast cancer in randomized trials. The investigators propose to examine the
      effects of now commonly used low-dose combined hormone therapy (HT) regimens on breast
      density, rates of abnormal mammogram, and circulating estrogens in the ongoing,
      already-funded Kronos Early Estrogen Prevention Study (KEEPS). KEEPS is a randomized clinical
      trial with a primary goal of examining the effects of low-dose transdermal versus oral
      estrogen combined with cyclic micronized progesterone on progression of subclinical
      atherosclerosis in recently menopausal women. Prior studies of low-dose HT have been of short
      duration and small size. By determining the effects of low-dose hormone therapy on the
      breast, the proposed ancillary study will add important information about the estimated
      balance of risks and benefits associated with low-dose HT and will help guide future research
      trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite data from clinical trials showing an increased risk of breast cancer and lack of
      overall benefit for primary prevention with hormone therapy (HT), there is still significant
      usage of HT by clinicians and women for treatment of moderate-to-severe systemic menopausal
      symptoms. Due to the possible increased risks with these preparations, current clinical
      recommendations advocate utilizing the lowest dose for the shortest possible duration, but
      average duration is often for 2-4 years. However, the effects of commonly used low-dose HT
      regimens on breast density and breast cancer risk are unknown. Recent data from intervention
      trials support the long standing hypothesis that hormonal effects on breast cancer risk are
      mediated through breast density. The Kronos Early Estrogen Prevention Study (KEEPS) is an
      ongoing, already- funded randomized clinical trial with a primary goal of examining the
      effects of 4 years of low- dose transdermal versus oral estrogen combined with cyclic
      micronized progesterone on progression of subclinical atherosclerosis in recently menopausal
      women. The proposed ancillary study will efficiently examine the effects of randomized
      low-dose HT on key breast cancer surrogate endpoints: mammographic density and rates of
      abnormal mammograms. In the parent KEEPS study, a total of 720 women were randomized to oral
      conjugated equine estrogens (0.45 mg/d), transdermal 17-beta estradiol (50 mcg/d), or
      placebo, with cyclic micronized progesterone (200 mg for 12 days) for active hormonal therapy
      groups. All participants were required to have mammography prior to study entry as well as
      yearly during follow-up; blood samples also were collected at these time points.
      Randomization was completed in 2008. In this ancillary study, we aimed to collect mammograms
      from eligible women consenting to be part of the ancillary study(n=517) from baseline, year 1
      and year 3 will be obtained and processed centrally to calculate mammographic density. The
      investigators will determine if these two low-dose HT regimens are associated with change in
      mammographic density. The investigators will also examine if baseline mammographic density or
      circulating biomarkers including estradiol, estrone, and estrone sulfate, modify or mediate
      changes in breast density with HT. In addition, the effects of hormonal regimens on the rates
      of abnormal mammogram and biopsy will be determined. By determining the effects of low-dose
      combined HT on the breast, the proposed study will add timely and important information about
      the estimated balance of risks and benefits associated with low-dose HT and will help guide
      future research.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BIRADS Breast Density</measure>
    <time_frame>Baseline (Prior to Randomization)</time_frame>
    <description>Breast density prior to randomization. Frequency of the BIRADS category according to randomization status. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BIRADS Breast Density</measure>
    <time_frame>Year 1</time_frame>
    <description>Frequency of the BIRADS category 1 year after randomization. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BIRADS Breast Density</measure>
    <time_frame>Latest (Year 3 of 4)</time_frame>
    <description>Frequency of the BIRADS category 3-4 years after randomization. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abnormal Mammogram/Biopsy</measure>
    <time_frame>baseline to 3 years</time_frame>
    <description>Abnormal mammogram requiring additional imaging modality such as MRI or ultrasound, or a breast biopsy. Information obtained from mammography reports.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">517</enrollment>
  <condition>Mammographic Density</condition>
  <condition>Abnormal Mammogram</condition>
  <arm_group>
    <arm_group_label>CEE pill, active progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estradiol patch, active progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet, placebo patch, placebo progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEE pill</intervention_name>
    <description>Conjugated equine estrogens 0.45 mg/day</description>
    <arm_group_label>CEE pill, active progesterone</arm_group_label>
    <other_name>premarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol patch</intervention_name>
    <description>Climara 50 mcg/day</description>
    <arm_group_label>estradiol patch, active progesterone</arm_group_label>
    <other_name>Climara 50 mcg/day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Progesterone</intervention_name>
    <description>Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime</description>
    <arm_group_label>CEE pill, active progesterone</arm_group_label>
    <arm_group_label>estradiol patch, active progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>estradiol patch, active progesterone</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>placebo patch</description>
    <arm_group_label>CEE pill, active progesterone</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo progesterone</intervention_name>
    <description>placebo progesterone</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women were 42-58 years of age, have had cessation of menses at or after age 40 and no
             menses for a minimum of 6 and a maximum of 36 months at screening.

          -  Subjects may or may not have had current vasomotor estrogen deficiency symptoms, had
             not taken estrogen- or progestogen-containing medication (oral contraceptive or
             hormone replacement) within 3 months of randomization, and had plasma FSH levels
             measured at ≥35 ng/ml and plasma E2 levels of &lt;40 pg/ml.

        Exclusion Criteria:

          -  Subjects were excluded for increased endometrial thickness on ultrasound &gt;5 mm, unless
             endometrial biopsy was negative; for LDL ≥ 190 mg/dl or triglycerides ≥ 400 at
             screening, or use of lipid lowering drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>42 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Rexrode, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <results_first_submitted>September 20, 2016</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Rulla Tamimi</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>mammographic density</keyword>
  <keyword>abnormal mammogram</keyword>
  <keyword>biopsy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We are willing to share data with collaborators if analyses are approved by the investigative team and approved by our IRB.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women in the parent study were approached to be part of this ancillary study (MDBHAS). For women who consented we attempted to collect their mammograms. Our collection took place after they started and were randomized in the parent study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CEE Pill, Active Progesterone</title>
          <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
CEE pill: Conjugated equine estrogens 0.45 mg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo patch: placebo patch</description>
        </group>
        <group group_id="P2">
          <title>Estradiol Patch, Active Progesterone</title>
          <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Estradiol patch: Climara 50 mcg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo tablet: Placebo tablet</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo tablet, placebo patch, placebo progesterone
Placebo tablet: Placebo tablet
Placebo patch: placebo patch
Placebo progesterone: placebo progesterone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline: Pre-randomization Mammogram</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168">Consented to MDBHAS</participants>
                <participants group_id="P2" count="162">Consented to MDBHAS</participants>
                <participants group_id="P3" count="187">Consented to MDBHAS.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Obtained Baseline Mammogram</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 1: Post Randomization Mammograms</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168">Consented to MDBHAS</participants>
                <participants group_id="P2" count="162">Consented to MDBHAS</participants>
                <participants group_id="P3" count="187">Consented to MDBHAS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Obtained Mammogam</title>
              <participants_list>
                <participants group_id="P1" count="136">Obtained post-randomization mammogram</participants>
                <participants group_id="P2" count="123">Obtained post randomization mammogram</participants>
                <participants group_id="P3" count="148">Obtained post randomization mammogram</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Final: Year 3 or 4 Post-randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168">Consented to MDBHAS</participants>
                <participants group_id="P2" count="162">Consented to MDBHAS</participants>
                <participants group_id="P3" count="187">Consented to MDBHAS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Obtained Year 3 or 4 Mammogram</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population with mammographic density data from at least one time point during study.</population>
      <group_list>
        <group group_id="B1">
          <title>CEE Pill, Active Progesterone</title>
          <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
CEE pill: Conjugated equine estrogens 0.45 mg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo patch: placebo patch</description>
        </group>
        <group group_id="B2">
          <title>Estradiol Patch, Active Progesterone</title>
          <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Estradiol patch: Climara 50 mcg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo tablet: Placebo tablet</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo tablet, placebo patch, placebo progesterone
Placebo tablet: Placebo tablet
Placebo patch: placebo patch
Placebo progesterone: placebo progesterone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="179"/>
            <count group_id="B4" value="488"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="2.7"/>
                    <measurement group_id="B2" value="52.8" spread="2.5"/>
                    <measurement group_id="B3" value="52.6" spread="2.4"/>
                    <measurement group_id="B4" value="52.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BIRADS Breast Density</title>
        <description>Breast density prior to randomization. Frequency of the BIRADS category according to randomization status. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
        <time_frame>Baseline (Prior to Randomization)</time_frame>
        <population>Women with mammograms are included.</population>
        <group_list>
          <group group_id="O1">
            <title>CEE Pill, Active Progesterone</title>
            <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
CEE pill: Conjugated equine estrogens 0.45 mg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo patch: placebo patch</description>
          </group>
          <group group_id="O2">
            <title>Estradiol Patch, Active Progesterone</title>
            <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Estradiol patch: Climara 50 mcg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo tablet: Placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet, placebo patch, placebo progesterone
Placebo tablet: Placebo tablet
Placebo patch: placebo patch
Placebo progesterone: placebo progesterone</description>
          </group>
        </group_list>
        <measure>
          <title>BIRADS Breast Density</title>
          <description>Breast density prior to randomization. Frequency of the BIRADS category according to randomization status. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
          <population>Women with mammograms are included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BIRADS 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BIRADS Breast Density</title>
        <description>Frequency of the BIRADS category 1 year after randomization. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
        <time_frame>Year 1</time_frame>
        <population>Women with mammograms 1 year after randomization</population>
        <group_list>
          <group group_id="O1">
            <title>CEE Pill, Active Progesterone</title>
            <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
CEE pill: Conjugated equine estrogens 0.45 mg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo patch: placebo patch</description>
          </group>
          <group group_id="O2">
            <title>Estradiol Patch, Active Progesterone</title>
            <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Estradiol patch: Climara 50 mcg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo tablet: Placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet, placebo patch, placebo progesterone
Placebo tablet: Placebo tablet
Placebo patch: placebo patch
Placebo progesterone: placebo progesterone</description>
          </group>
        </group_list>
        <measure>
          <title>BIRADS Breast Density</title>
          <description>Frequency of the BIRADS category 1 year after randomization. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
          <population>Women with mammograms 1 year after randomization</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BIRADS 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BIRADS Breast Density</title>
        <description>Frequency of the BIRADS category 3-4 years after randomization. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
        <time_frame>Latest (Year 3 of 4)</time_frame>
        <population>Women with mammograms 3-4 years after randomization</population>
        <group_list>
          <group group_id="O1">
            <title>CEE Pill, Active Progesterone</title>
            <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
CEE pill: Conjugated equine estrogens 0.45 mg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo patch: placebo patch</description>
          </group>
          <group group_id="O2">
            <title>Estradiol Patch, Active Progesterone</title>
            <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Estradiol patch: Climara 50 mcg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo tablet: Placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet, placebo patch, placebo progesterone
Placebo tablet: Placebo tablet
Placebo patch: placebo patch
Placebo progesterone: placebo progesterone</description>
          </group>
        </group_list>
        <measure>
          <title>BIRADS Breast Density</title>
          <description>Frequency of the BIRADS category 3-4 years after randomization. BIRADS is a 1-4 category of breast density as assessed by a radiologist. 1= most fatty and least dense, while 4=most dense.</description>
          <population>Women with mammograms 3-4 years after randomization</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BIRADS 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIRADS 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Mammogram/Biopsy</title>
        <description>Abnormal mammogram requiring additional imaging modality such as MRI or ultrasound, or a breast biopsy. Information obtained from mammography reports.</description>
        <time_frame>baseline to 3 years</time_frame>
        <population>Women with mammography reports</population>
        <group_list>
          <group group_id="O1">
            <title>CEE Pill, Active Progesterone</title>
            <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
CEE pill: Conjugated equine estrogens 0.45 mg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo patch: placebo patch</description>
          </group>
          <group group_id="O2">
            <title>Estradiol Patch, Active Progesterone</title>
            <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Estradiol patch: Climara 50 mcg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo tablet: Placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet, placebo patch, placebo progesterone
Placebo tablet: Placebo tablet
Placebo patch: placebo patch
Placebo progesterone: placebo progesterone</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Mammogram/Biopsy</title>
          <description>Abnormal mammogram requiring additional imaging modality such as MRI or ultrasound, or a breast biopsy. Information obtained from mammography reports.</description>
          <population>Women with mammography reports</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline through 4 years.</time_frame>
      <desc>There were no adverse events related to the ancillary mammographic density study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CEE Pill, Active Progesterone</title>
          <description>Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
CEE pill: Conjugated equine estrogens 0.45 mg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo patch: placebo patch</description>
        </group>
        <group group_id="E2">
          <title>Estradiol Patch, Active Progesterone</title>
          <description>Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Estradiol patch: Climara 50 mcg/day
Active Progesterone: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
Placebo tablet: Placebo tablet</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo tablet, placebo patch, placebo progesterone
Placebo tablet: Placebo tablet
Placebo patch: placebo patch
Placebo progesterone: placebo progesterone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rulla Tamimi</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-525-0862</phone>
      <email>rulla.tamimi@channing.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

